Glesatinib

Glesatinib
Clinical data
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[(3-Fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}-2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-fluorophenyl)acetamide;
CAS Number	936694-12-1;
PubChem CID	25181472;
ChemSpider	52084900;
UNII	7Q29OXD98N;
KEGG	D11136;
CompTox Dashboard (EPA)	DTXSID601337113 ;
Chemical and physical data
Formula	C31H27F2N5O3S2
Molar mass	619.71 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F;
	InChI InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42); Key:YRCHYHRCBXNYNU-UHFFFAOYSA-N;

Glesatinib (MGCD265) is an experimental anti-cancer drug.^[1]^[2]

It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).^[3]

It is a spectrum selective tyrosine^[1] kinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET".^[4]

References

^ ^a ^b "Glesatinib". NCI Dictionaries. National Cancer Institute at the National Institutes of Health. U.S. Department of Health and Human Services. Archived from the original on 2017-01-16. Retrieved 2017-01-15.
^ Cui Q, Cai CY, Gao HL, Ren L, Ji N, Gupta P, Yang Y, Shukla S, Ambudkar SV, Yang DH, Chen ZS (2019). "Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells". Frontiers in Oncology. 9: 313. doi:10.3389/fonc.2019.00313. PMC 6494935. PMID 31106148.
^ Clinical trial number NCT02954991 for "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer " at ClinicalTrials.gov
^ "Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs". PipelineReview.com. January 2017.

External links

glesatinib@cancer.gov Archived 2017-01-16 at the Wayback Machine

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[cg-1] "Glesatinib". NCI Dictionaries. National Cancer Institute at the National Institutes of Health. U.S. Department of Health and Human Services. Archived from the original on 2017-01-16. Retrieved 2017-01-15.

[pmid31106148-2] Cui Q, Cai CY, Gao HL, Ren L, Ji N, Gupta P, Yang Y, Shukla S, Ambudkar SV, Yang DH, Chen ZS (2019). "Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells". Frontiers in Oncology. 9: 313. doi:10.3389/fonc.2019.00313. PMC 6494935. PMID 31106148.

[ct991-3] Clinical trial number NCT02954991 for "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer " at ClinicalTrials.gov

[4] "Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs". PipelineReview.com. January 2017.

[1]

[2]

[3]

[4]

Clinical data

Routes of administration	By mouth
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-[(3-Fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}-2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-fluorophenyl)acetamide
CAS Number	936694-12-1
PubChem CID	25181472
ChemSpider	52084900
UNII	7Q29OXD98N
KEGG	D11136
CompTox Dashboard (EPA)	DTXSID601337113
Chemical and physical data
Formula	C₃₁H₂₇F₂N₅O₃S₂
Molar mass	619.71 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F
InChI InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42) Key:YRCHYHRCBXNYNU-UHFFFAOYSA-N

Glesatinib

See also

References

External links